Eli Lilly participated in a series B round for the cardiorenal treatment specialist that will support clinical drug trials, boosting its overall funding to $193m.

US-based cardiorenal treatment developer CinCor Pharma received $143m on Tuesday in a series B round that included Lilly Asia Ventures, a venture capital firm sponsored by pharmaceutical firm Eli Lilly.

Growth equity firm General Atlantic Led the round, which included Perceptive Advisors, BVF Partners, VenBio Partners, Omega Funds, RTW Investments, Adage Capital Management, Rock Springs Capital, Sixty Degree Capital, Sofinnova Investments, Sofinnova Partners and 5AM Ventures.

Founded in 2018, CinCor specialises in developing treatments for diseases affecting the heart and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn